Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Down 33.0% in February

Alzamend Neuro, Inc. (NASDAQ:ALZN) saw a significant drop in short interest in February. As of February 15th, there was short interest totalling 52,800 shares, a drop of 33.0% from the January 31st total of 78,800 shares. Approximately 1.0% of the company’s stock are short sold. Based on an average trading volume of 355,200 shares, the short-interest ratio is currently 0.1 days.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets cut their price target on Alzamend Neuro from $35.00 to $32.00 and set a “buy” rating on the stock in a research note on Monday, December 16th.

Alzamend Neuro Trading Down 2.1 %

Alzamend Neuro stock opened at $0.82 on Monday. Alzamend Neuro has a 52 week low of $0.79 and a 52 week high of $15.06. The stock has a 50 day moving average of $1.12 and a 200-day moving average of $1.54.

Alzamend Neuro (NASDAQ:ALZN) last posted its quarterly earnings data on Wednesday, December 11th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($2.38) by $1.98. On average, analysts forecast that Alzamend Neuro will post -1.68 earnings per share for the current year.

Hedge Funds Weigh In On Alzamend Neuro

An institutional investor recently bought a new position in Alzamend Neuro stock. Citadel Advisors LLC bought a new position in Alzamend Neuro, Inc. (NASDAQ:ALZN) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 30,638 shares of the company’s stock, valued at approximately $36,000. Citadel Advisors LLC owned approximately 0.56% of Alzamend Neuro at the end of the most recent quarter. 49.61% of the stock is owned by institutional investors.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.